ArticleDermatology and therapy2025
Healthcare Resource Utilization and Economic Burden of Prurigo Nodularis in the United States.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Experience in the management of real-world patients with chronic prurigo nodularis in a dermatology setting: results from the ECOSPIN Spanish survey-based study.Frontiers in medicine · 2026Article
- New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe impacts of prurigo nodularis (PN) on healthcare resource utilization (HCRU) and associated costs are unclear.
methodsThis retrospective, cross-sectional claims analysis (IQVIA PharMetrics
resultsWe matched 16,888 patients with PN with 16,888 controls. Most comorbidities (mental health, metabolic conditions, type 2 inflammatory diseases) appeared more frequently in patients with PN versus controls. HCRU was significantly (P < 0.001) higher for patients with PN versus controls, including mean (standard deviation, SD) number of outpatient visits (17.0 [15.5] vs 8.1 [10.7]) and proportion of patients with hospitalizations (9.3% vs 5.9%). Mean (SD) total costs were significantly (P < 0.001) greater for patients with PN versus controls ($18,315 [$66,476] vs $8451 [$30,982]).
conclusionsPatients with PN receiving advanced therapy had higher HCRU and costs versus localized/no therapy. Patients with PN (particularly those receiving advanced therapies) incurred higher all-cause HCRU burden and associated costs than matched controls. Enhanced feature (slides, video, animation) (MP4 12313 KB).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.